Traditional antibody-based cancer therapies target specific antigens on the surface of cancer cells, helping the immune system recognize and destroy these abnormal cells. However, cancer cells often display a cloak of sugar-protein molecules (polyglycoproteins) that signal “do not attack,” significantly limiting the effectiveness of immune responses. Recently, scientists at Stanford University combined antibodies with lectins – sugar-binding proteins – to develop a novel cancer drug, AbLec. This new approach simultaneously targets tumors and “disarms” these immune-suppressing signals, leading to improved anti-cancer effects. The findings were recently published in the international journal Nature Biotechnology.
The Immune System’s ‘Recognition and Attack’ Challenge
Antibodies are a crucial component of the immune system, precisely locking onto specific antigens on cancer cells, guiding immune cells to launch an attack. However, cancer cells evolve various protective mechanisms, one of which is covering their surface with heavily sialylated glycans. These sugar molecules interact with inhibitory receptors (siglecs) on immune cells, temporarily causing them to “stand down.” Therefore, even if the immune system has “targeted” the enemy through antibodies, it cannot unleash its full destructive power.
AbLec: A Dual Strategy of Targeting and Disarming
The antibody-lectin chimera (AbLec) developed by the Stanford University team was designed to overcome this challenge. The antibody portion of AbLec still precisely identifies tumor cells, while the lectin serves a dual purpose: it can “grab” sugar molecules on the cancer cell surface, enhancing targeting, and it can shield the inhibitory signals from the polysaccharides, allowing immune cells to attack effectively. This design allows AbLec to “remove the tumor’s invisible shield,” effectively releasing suppressed immune function.
In animal studies, AbLec demonstrated stronger anti-cancer effects than single antibodies. It not only inhibited tumor growth but also synergized with existing immune checkpoint inhibitors, offering potential new hope for patients who don’t respond to traditional treatments. However, scientists caution that there are many challenges to overcome before moving from animal studies to human clinical trials, including safety concerns, the risk of immune overreaction, and determining the optimal dosage and administration method.
Beyond AbLec: The Future of Immunotherapy
This research signals a shift in cancer treatment thinking: moving beyond simply “inducing” an immune response to also removing the signals tumors use to suppress the immune system. AbLec’s dual function – precise tumor targeting and immune obstacle removal – provides a new strategy for overcoming cancer cells’ “immune evasion” tactics and opens a new direction for anti-cancer drug development. However, these are still early research results, and rigorous human trials are needed to validate its efficacy and safety.
The Expanding Landscape of Cancer Immunotherapy
AbLec represents just one facet of the rapidly evolving field of cancer immunotherapy. Several key trends are shaping the future of this promising treatment approach:
1. Personalized Neoantigen Vaccines
Instead of targeting common antigens, researchers are increasingly focusing on neoantigens – unique mutations found in an individual’s tumor cells. These neoantigens are highly specific to the patient’s cancer, minimizing the risk of attacking healthy tissue. Companies like Moderna and BioNTech (famous for their COVID-19 vaccines) are pioneering personalized cancer vaccines based on mRNA technology. Early clinical trials have shown promising results, particularly in melanoma and glioblastoma.
2. CAR-T Cell Therapy 2.0
Chimeric Antigen Receptor (CAR) T-cell therapy involves engineering a patient’s own T cells to recognize and attack cancer cells. While effective against certain blood cancers, CAR-T therapy has limitations, including cytokine release syndrome (CRS) and neurotoxicity. Next-generation CAR-T therapies are being developed to address these issues, with features like “switchable” CARs that can be turned on or off to control the immune response, and CAR-T cells engineered to target solid tumors.
3. Oncolytic Viruses: Harnessing Viruses to Fight Cancer
Oncolytic viruses are genetically engineered viruses that selectively infect and kill cancer cells. They also stimulate an immune response against the tumor. Talimogene laherparepvec (T-VEC), an oncolytic herpes simplex virus, is already approved for the treatment of melanoma. Research is ongoing to develop oncolytic viruses for other cancer types, and to combine them with other immunotherapies.
4. The Microbiome’s Role in Immunotherapy Response
Growing evidence suggests that the composition of the gut microbiome can significantly influence a patient’s response to immunotherapy. Certain gut bacteria can enhance anti-tumor immunity, while others can suppress it. Researchers are exploring ways to manipulate the microbiome – through diet, probiotics, or fecal microbiota transplantation – to improve immunotherapy outcomes. A 2021 study in Science demonstrated that specific gut bacteria correlated with improved responses to anti-PD-1 therapy in melanoma patients.
The Challenges Ahead
Despite the remarkable progress in cancer immunotherapy, significant challenges remain. Many patients do not respond to treatment, and even those who do may experience relapse. The high cost of some immunotherapies, such as CAR-T cell therapy, also limits access. Further research is needed to identify biomarkers that can predict treatment response, develop more effective combination therapies, and reduce the toxicity of immunotherapy.
Stay up-to-date with the latest tech news.
（Image source: shutterstock）
Worth a look